<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lee SJ</submitter><funding>NRF</funding><pagination>e26800</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10906407</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>10(5)</volume><pubmed_abstract>Epidermal Growth Factor (EGF), a protein pivotal in cell proliferation and survival, has recently shown promise in alleviating inflammation. This study investigates EGF's impact on M1 macrophages, exploring its potential for anti-inflammatory and anti-vasculogenic interactions with corneal endothelial cells (CECs). Polarized M1 macrophages treated with EGF exhibited a suppression of gene expressions related to inflammatory and vasculogenic signals. The anti-inflammatory effects of EGF were observed in co-culture systems with human CECs (HCECs), showcasing its ability to alter macrophage phenotypes. Exosomes derived from EGF-treated M1 macrophages demonstrated enriched proteomic profiles related to immune system regulation and inflammation inhibition. When applied as eye drops in murine corneas, EGF-conditioned M1 macrophage-derived exosomes effectively reduced inflammation and increased M2-related &lt;i>ARG1&lt;/i> expression. This study highlights EGF's potential in mitigating inflammation in M1 macrophages and its delivery through exosomes to cultured HCECs and murine corneas, suggesting a novel therapeutic avenue for ocular surface anti-inflammatory treatments.</pubmed_abstract><journal>Heliyon</journal><pubmed_title>EGF-conditioned M1 macrophages Convey reduced inflammation into corneal endothelial cells through exosomes.</pubmed_title><pmcid>PMC10906407</pmcid><funding_grant_id>RS-2023-00209498</funding_grant_id><funding_grant_id>RS-2023-00219421</funding_grant_id><pubmed_authors>Koh A</pubmed_authors><pubmed_authors>Lee SJ</pubmed_authors><pubmed_authors>Lee SH</pubmed_authors><pubmed_authors>Kim KW</pubmed_authors></additional><is_claimable>false</is_claimable><name>EGF-conditioned M1 macrophages Convey reduced inflammation into corneal endothelial cells through exosomes.</name><description>Epidermal Growth Factor (EGF), a protein pivotal in cell proliferation and survival, has recently shown promise in alleviating inflammation. This study investigates EGF's impact on M1 macrophages, exploring its potential for anti-inflammatory and anti-vasculogenic interactions with corneal endothelial cells (CECs). Polarized M1 macrophages treated with EGF exhibited a suppression of gene expressions related to inflammatory and vasculogenic signals. The anti-inflammatory effects of EGF were observed in co-culture systems with human CECs (HCECs), showcasing its ability to alter macrophage phenotypes. Exosomes derived from EGF-treated M1 macrophages demonstrated enriched proteomic profiles related to immune system regulation and inflammation inhibition. When applied as eye drops in murine corneas, EGF-conditioned M1 macrophage-derived exosomes effectively reduced inflammation and increased M2-related &lt;i>ARG1&lt;/i> expression. This study highlights EGF's potential in mitigating inflammation in M1 macrophages and its delivery through exosomes to cultured HCECs and murine corneas, suggesting a novel therapeutic avenue for ocular surface anti-inflammatory treatments.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-06-08T06:10:54.508Z</modification><creation>2025-04-07T04:44:22.11Z</creation></dates><accession>S-EPMC10906407</accession><cross_references><pubmed>38434401</pubmed><doi>10.1016/j.heliyon.2024.e26800</doi></cross_references></HashMap>